Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients (Q33377847)

26 July 2017

title

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients (English)

1 reference

26 July 2017

1 reference

Hereng T

1

1 reference

26 July 2017

Lambert M

2

1 reference

26 July 2017

Hachulla E

3

1 reference

26 July 2017

Samor M

4

1 reference

26 July 2017

Dubucquoi S

5

1 reference

26 July 2017

Caron C

6

1 reference

26 July 2017

Launay D

7

1 reference

26 July 2017

Morell-Dubois S

8

1 reference

26 July 2017

Queyrel V

9

1 reference

26 July 2017

Hatron PY

10

1 reference

26 July 2017

publication date

1 January 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

17

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

11-15

1 reference

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Epidemiology of the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307084724

21 January 2018

Identifiers

DOI

10.1177/0961203307084724

1 reference

26 July 2017

1 reference